NZ's PHARMAC proposals on funding Opdivo, Keytruda, Noxafil and Isentress

28 June 2016

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced a decision to fund nivolumab (trade name Opdivo), from US pharma major Bristol-Myers Squibb (NYSE: BMY), for patients with unresectable or metastatic (stage III or IV) melanoma (advanced melanoma) from July 1, 2016.

Also, PHARMAC has now reached a commercially favorable provisional agreement with Merck Sharpe and Dohme (New Zealand), the local subsidiary of US pharma giant Merck & Co (NYSE: MRK), for the supply of Keytruda (pembrolizumab).

The Agency is seeking feedback on a proposal to:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK